130 related articles for article (PubMed ID: 35023460)
1. Inhibiting the Activity of ABCG2 by KU55933 in Colorectal Cancer.
Liu K; Chen Y; Shi XB; Xing ZH; He ZJ; Wang ST; Li YC; Liu WJ; Zhang PW; Yu ZZ; Mo XM; Shi XY; Chen ZS; Shi Z
Recent Pat Anticancer Drug Discov; 2022; 17(4):387-395. PubMed ID: 35023460
[TBL] [Abstract][Full Text] [Related]
2. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
[TBL] [Abstract][Full Text] [Related]
3. Pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinolines: Novel compounds that reverse ABCG2-mediated resistance in cancer cells.
Karthikeyan C; Malla R; Ashby CR; Amawi H; Abbott KL; Moore J; Chen J; Balch C; Lee C; Flannery PC; Trivedi P; Faridi JS; Pondugula SR; Tiwari AK
Cancer Lett; 2016 Jun; 376(1):118-26. PubMed ID: 27012188
[TBL] [Abstract][Full Text] [Related]
4. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
[TBL] [Abstract][Full Text] [Related]
5. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
[TBL] [Abstract][Full Text] [Related]
6. A Novel Synthetic Dihydroindeno[1,2-b] Indole Derivative (LS-2-3j) Reverses ABCB1- and ABCG2-Mediated Multidrug Resistance in Cancer Cells.
Guo C; Liu F; Qi J; Ma J; Lin S; Zhang C; Zhang Q; Zhang H; Lu R; Li X
Molecules; 2018 Dec; 23(12):. PubMed ID: 30544754
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of human ATP-binding cassette transporter ABCG2 contributes to reducing the cytotoxicity of GSK1070916 in cancer cells.
Wu ZX; Mai Q; Yang Y; Wang JQ; Ma H; Zeng L; Chen ZS; Pan Y
Biomed Pharmacother; 2021 Apr; 136():111223. PubMed ID: 33450491
[TBL] [Abstract][Full Text] [Related]
8. The Spleen Tyrosine Kinase Inhibitor, Entospletinib (GS-9973) Restores Chemosensitivity in Lung Cancer Cells by Modulating ABCG2-mediated Multidrug Resistance.
Narayanan S; Wu ZX; Wang JQ; Ma H; Acharekar N; Koya J; Yoganathan S; Fang S; Chen ZS; Pan Y
Int J Biol Sci; 2021; 17(10):2652-2665. PubMed ID: 34326700
[TBL] [Abstract][Full Text] [Related]
9. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
10. The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.
Sen R; Natarajan K; Bhullar J; Shukla S; Fang HB; Cai L; Chen ZS; Ambudkar SV; Baer MR
Mol Cancer Ther; 2012 Sep; 11(9):2033-44. PubMed ID: 22778153
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
12. SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in cancer cell lines.
Wu CP; Murakami M; Hsiao SH; Liu TC; Yeh N; Li YQ; Hung TH; Wu YS; Ambudkar SV
Cancer Lett; 2018 Oct; 433():259-272. PubMed ID: 30026175
[TBL] [Abstract][Full Text] [Related]
13. Single-nucleotide polymorphisms in a short basic motif in the ABC transporter ABCG2 disable its trafficking out of endoplasmic reticulum and reduce cell resistance to anticancer drugs.
Zhang W; Yang Y; Dong Z; Shi Z; Zhang JT
J Biol Chem; 2019 Dec; 294(52):20222-20232. PubMed ID: 31719146
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
[TBL] [Abstract][Full Text] [Related]
15. Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.
Calcagno AM; Fostel JM; To KK; Salcido CD; Martin SE; Chewning KJ; Wu CP; Varticovski L; Bates SE; Caplen NJ; Ambudkar SV
Br J Cancer; 2008 May; 98(9):1515-24. PubMed ID: 18382425
[TBL] [Abstract][Full Text] [Related]
16. Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.
Ji N; Yang Y; Cai CY; Lei ZN; Wang JQ; Gupta P; Shukla S; Ambudkar SV; Kong D; Chen ZS
Cancer Lett; 2019 Jan; 440-441():82-93. PubMed ID: 30315846
[TBL] [Abstract][Full Text] [Related]
17. The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance.
Shi Z; Parmar S; Peng XX; Shen T; Robey RW; Bates SE; Fu LW; Shao Y; Chen YM; Zang F; Chen ZS
Oncol Rep; 2009 Feb; 21(2):483-9. PubMed ID: 19148526
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis.
Hsu HH; Chen MC; Baskaran R; Lin YM; Day CH; Lin YJ; Tu CC; Vijaya Padma V; Kuo WW; Huang CY
J Cell Physiol; 2018 Jul; 233(7):5458-5467. PubMed ID: 29247488
[TBL] [Abstract][Full Text] [Related]
19. PCI29732, a Bruton's Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells.
Ge C; Wang F; Cui C; Su X; To KKW; Wang X; Zhang H; Song X; Fu L
Cell Physiol Biochem; 2018; 48(6):2302-2317. PubMed ID: 30114704
[TBL] [Abstract][Full Text] [Related]
20. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
Ji N; Yang Y; Lei ZN; Cai CY; Wang JQ; Gupta P; Xian X; Yang DH; Kong D; Chen ZS
Biochem Pharmacol; 2018 Dec; 158():274-285. PubMed ID: 30431011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]